Global Health Catalyst Summit Outcome Example: Collaborative Education
Premier Hypofractionated Radiotherapy Education Course organized in collaboration with Radiation Knowledge
(July 8 - September 3 2022)
Experts Lectures, treatment planning Olympics and practical training, Course Certificate/Awards
Course background and purpose:
Clinical trials have established clinical equipoise between hypofractionated radiotherapy (HFRT) schedules and conventionally fractionated treatment for some cancers like prostate and breast cancers. In the advent of the COVID-19 pandemic, professional societies including the American Society for Radiation Oncology and the National Comprehensive Cancer Network recommended increased adoption of evidence-based HFRT. HFRT benefits include significantly reducing the number of clinical visits for each patient, minimizing potential exposure, and reducing costs and stress on limited workforce, which is particularly beneficial in resource-limited settings or Low-and-Middle-Income Countries (LMICs). Studies have also shown that increased adoption of HFRT could substantially increase access to care and reduce disparities. Despite the benefits, HFRT adoption remains low, especially in LMICs. Education and training is a crucial consideration in the implementation and acceptance of a HFRT, and possibly just as critical to the development of HFRT as the technical infrastructure. Information and Communication Technologies (ICTs), and artificial intelligence (AI) technologies provide an excellent opportunity for facilitating education and training, and providing support for radiation oncology health professionals in increasing adoption of HFRT.
Cognizant of this, the purpose of this course is to provide education and training in HFRT with major opportunity for professional development (with certificates and awards) leveraging ICTs/AI. The course will include lectures from experts at world-leading institutions, a treatment planning Olympics/competition (which in the past has drawn thousands of participants) and culminate with certificates and awards during the 2022 NIH-funded Global Health Catalyst summit
Course Schedule
July 8 - September 3Â 2022
Weekly onine lectures (Saturdays)
July 8 – July 30th, 2022
July 8th, 2022: Session 1: General session on Hypofractionated Radiation therapy for breast, cervix, and prostate cancers. (Pre-course assessment for those interested in course certificates
July 16th, 2022: Session 2: Hypofractionated treatment workflow from consult to treatment for breast cancer
July 23rd, 2022: Session 3: Hypofractionated treatment workflow from consult to treatment for cervical cancer
July 30th, 2022: Session 4: Hypofractionated treatment workflow from consult to treatment for prostate cancer; Post-Lectures assessment for those interested in course completion certificates
Treatment Planning Activity/Competition on HFRT for prostate cancer, with awards
August 7th – September 3, 2022
August 7, 2022: Presentation about Contouring/Planning Activities: Presentation on the Contouring process, assignments, case description, plan criteria, plan evaluation, etc
August 8 – 9, 2022: Contouring activity: Participants will perform homework/contouring tasks.
August 10-12, 2022: Planning activity: Participants downloads the case, generate plan (3D CRT &/or IMRT) in their TPS, upload & evaluate plan.
September 3, 2022. Announcement of statistics and winners, knowledge sharing, awards/certificates, and closing ceremony
Register for the hypofractionated Radiotherapy Course and join any session beginning with the education sessions at 8:30 am Est on July 16, July 23, and July 30 2022.
July 8, 2022 - September 3, 2022
Some of the Course Experts and collaborating team members amongst the world's best
Update in progress/Subject to Change
Dr Saiful Huq
Professor, Radiation Oncology
and Clinical and Translational Science, Director, University of Pittsburgh School of Medicine, Past President, American Association of Physicists in Medicine
Dr Akila Viswanathan
Chair, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine
Dr Stephen Avery
Associate Professor of Radiation Oncology. University of Pennsylvania
Ahmad Nobah
Founder, Radiation Knowledge
Dr Fallon Chipidza
Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Dr Surbhi Grover
Assistant Professor and Director of Global Radiation Oncology, University of Pennsylvania
Dr Jeff Michalski
Carlos Perez Distinguished Professor, Department of Radiation Oncology, Washington University School of Medicine, ASTRO President-elect
May Abdel-Wahab,
Director of the Division of Human Health at the International Atomic Energy Agency
Dr Curtiland Deville
Associate Professor of Radiation Oncology, Johns Hopkins Medicine
Dr Adedayo Joseph
Clinical Radiation Oncologist and the Research Program Director of NSIA-LUTH Cancer Centre,
Dr Nwamaka Lasebikan
President of Association of radiation and clinical oncologist of Nigeria
Dr Omoruyi, Credit Irabor
Radiation Oncology, Sidney Kimmel Cancer Center & Thomas Jefferson University Hospitals.
Jacky Nyamwanda, MS, CAGS, CMD
Suffolk/Massachusetts General Hospital, Harvard Medical School
Dr Ahmed Elzawawy
Professor of Clinical Oncology, Chair of the Board of Directors. Global Oncology University
Dr Heng Li
Associate Professor of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine
Dr Mack Roach III
Professor of Radiation Oncology and Urology, at the University of California, San Francisco
Dr Rebecca Buecker
Senior Consultant Radiation Oncologist Klinikum Lippe Lemgo, Germany. GHC Diaspora Global Radiation Oncology leader
Dr Neil Taunk
Assistant Professor of Radiation Oncology, University of Pennsylvania
Professor Twalib Ngoma
Senior Consultant Clinical Oncologist
Muhimbili University of Health And Allied Sciences, Tanzania
Dr Abba Mallum
Medical Specialist and Consultant Clinical Radiation Oncologist and Researcher; Inkosi Albert Luthuli Central Hospital. South Africa
Professor David Kerr
University of Oxford
